Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
In rejecting Summit Therapeutics’ PD-1xVEGF the FDA raised concern about the high rate of Chinese patients included in the final…
In rejecting Summit Therapeutics’ PD-1xVEGF the FDA raised concern about the high rate of Chinese patients included in the final…
> Listen on Spotify > Listen on Apple Products > Listen on Amazon Music > Listen on iHeart > Watch…
With the rejection of Summit Therapeutics’ PD-1xVEGF therapy, the FDA has drawn a line in the sand, firmly setting improved…